Form 4: Xilio Therapeutics Director Aoife Brennan Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director Aoife Brennan was granted 31,000 stock options with an exercise price of $0.693, aligning her interests with shareholder value.

Summary

• Aoife Brennan, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options on June 11, 2025.
• The options have an exercise price of $0.693 per share.
• These options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Brennan's continued service to Xilio Therapeutics through the vesting date.
• The options are set to expire on June 10, 2035.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard corporate governance practices and aligns director incentives with shareholder interests, without revealing any negative operational or financial news.

Positives

• The grant of stock options to a director aligns management and board interests with those of shareholders, incentivizing long-term performance and value creation.
• The exercise price of $0.693 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The stock options granted to Director Aoife Brennan are subject to future vesting conditions, specifically on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, provided her continued service to the company.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages designed to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation for directors is a standard practice across the biotechnology and broader corporate sectors, comparable to compensation structures seen in companies like Moderna, BioNTech, or other early-stage biotech firms that rely on equity to attract and retain talent.

Related Party Transactions

• The grant of stock options to a director is a form of compensation and an insider transaction, aligning the director's financial interests with the company's performance.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's interests with shareholder value creation, potentially leading to better long-term strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices are part of the overall corporate governance and compensation philosophy.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Xilio Therapeutics, XLO, Stock Option, Insider Transaction, Director Compensation, Equity Grant, Form 4, Beneficial Ownership